Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease

Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography

(2016) Bieneke Janssen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A4 An overview of energy metabolism in huntington’s disease as a therapeutic target

(2016) Robert E Pacifici et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor

(2015) Roger Slavik et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Quantification of [18F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients

(2015) Sandeep SV Golla et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?

(2015) Z. Fan et al.   JOURNAL OF NUCLEAR MEDICINE

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation

(2015) Alena V. Savonenko et al.   PLoS One

PET Radioligands for In Vivo Visualization of Neuroinflammation

(2014) Dieter Ory et al.   CURRENT PHARMACEUTICAL DESIGN

Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor

(2013) Laurent Hortala et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease

(2013) William C. Kreisl et al.   BRAIN

In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients

(2013) Andrea Varrone et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

In vivo type 1 cannabinoid receptor availability in Alzheimer's disease

(2013) Rawaha Ahmad et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects

(2013) Rawaha Ahmad et al.   MOLECULAR IMAGING AND BIOLOGY

Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study

(2012) Alie Schuitemaker et al.   NEUROBIOLOGY OF AGING

Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer

(2011) Nele Evens et al.   NUCLEAR MEDICINE AND BIOLOGY

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

(2009) Javier Palazuelos et al.   BRAIN

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2009) David A. Price et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention

(2009) Malú G. Tansey et al.   NEUROBIOLOGY OF DISEASE

Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging

(2009) Nele Evens et al.   NUCLEAR MEDICINE AND BIOLOGY

PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET

(2008) Sriram Venneti et al.   NEUROBIOLOGY OF AGING